West Family Investments Inc. Invests $716,000 in Thermo Fisher Scientific Inc. $TMO

West Family Investments Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,428 shares of the medical research company’s stock, valued at approximately $716,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID boosted its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $26,000. High Note Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $28,000. Finally, JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth about $28,000. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target for the company. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Piper Sandler upped their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, Morgan Stanley raised their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 4.3%

TMO stock opened at $614.32 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $227.14 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company’s 50 day simple moving average is $536.26 and its 200-day simple moving average is $508.51.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the business posted $4.28 EPS. The company’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.